https://www.selleckchem.com/pr....oducts/cp21r7-cp21.h
Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease, with a prevalence estimated to between 20% and 30% of the general population and approximately 70% of stage 2 obese people with type 2 diabetes (T2D) with normal liver enzymes. To investigate the metabolic and liver-related outcomes of bariatric surgery among patients with insulin-treated T2D and NAFLD who are at high risk of liver fibrosis. More than 600 locations within the United Kingdom. The study comprises a retrospective cohort
إعجاب
علق
شارك
